Sarepta Therapeutics, Inc.
SRPT
$20.22
$0.160.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 196.89M | -447.51M | 159.05M | 33.61M | 6.46M |
| Total Depreciation and Amortization | 10.84M | 9.98M | 10.46M | 9.81M | 8.72M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.07M | 135.87M | 47.54M | 102.51M | 45.14M |
| Change in Net Operating Assets | 49.53M | -281.78M | -124.99M | -216.62M | -45.38M |
| Cash from Operations | 261.34M | -583.44M | 92.05M | -70.70M | 14.94M |
| Capital Expenditure | -31.80M | -43.65M | -38.08M | -37.26M | -29.17M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 64.01M | -247.53M | 802.20M | -91.56M | -69.36M |
| Cash from Investing | 32.21M | -291.18M | 764.12M | -128.83M | -98.53M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -304.00K | -3.21M | -68.00K | -- | -- |
| Issuance of Common Stock | 1.50M | 15.68M | 3.71M | 13.76M | 39.92M |
| Repurchase of Common Stock | -25.01M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 45.35M | -- | -- |
| Cash from Financing | -23.82M | 12.47M | 48.99M | 13.76M | 39.92M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 269.73M | -862.14M | 905.16M | -185.77M | -43.67M |